지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2017.1
- 수록면
- 423 - 429 (7page)
이용수
초록· 키워드
오류제보하기
The glucagon-like peptide-1 receptor agonists (GLP-1RAs) were recommended as a monotherapy or combination therapy with oral hypoglycemic agents or basal insulin in the position statement of the Korean Diabetes Association 2017 for pharmacological therapy. Many randomized clinical trials and systematic reviews report that GLP-1RAs have considerable glucose-lowering effect and lead to weight reduction and low risk of hypoglycemia when used as a monotherapy or combination therapy. The cardiovascular safety of GLP-1RAs has been assessed in several randomized clinical trials and systematic reviews. The results of cardiovascular outcome trials of long-acting GLP-1RAs (liraglutide, semaglutide) demonstrated cardiovascular benefits in subjects with type 2 diabetes mellitus and a high risk of cardiovascular disease. The GLP-1RA may be a choice of therapy when weight control and avoidance of hypoglycemia are important, and patients with high risk of cardiovascular disease might also favor choosing GLP-1RA.
목차
등록된 정보가 없습니다.
참고문헌 (10)
참고문헌 신청
Thrasher J / 2017 / Pharmacologic management of type 2 diabetes mellitus: available therapies / Am J Med 130(6S):S4~17
고승현 / 2017 / Antihyperglycemic Agent Therapy for Adult Patients with Type 2 Diabetes Mellitus 2017: A Position Statement of the Korean Diabetes Association / Diabetes and Metabolism Journal 41(5):337~348
American Diabetes Association / 2017 / 8. Pharmacologic approaches to glycemic treatment / Diabetes Care 40(Suppl 1):S64~74
Canadian Diabetes Association Clinical Practice Guidelines Expert Committee / 2013 / Pharmacologic management of type 2 diabetes / Can J Diabetes 37(Suppl 1):S61~68
Cimmaruta D / 2016 / Efficacy and safety of insulin-GLP-1 receptor agonists combination in type 2 diabetes mellitus: a systematic review / Expert Opin Drug Saf 15(sup2):77~83
고승현 / 2017 / Antihyperglycemic Agent Therapy for Adult Patients with Type 2 Diabetes Mellitus 2017: A Position Statement of the Korean Diabetes Association / Diabetes and Metabolism Journal 41(5):337~348
American Diabetes Association / 2017 / 8. Pharmacologic approaches to glycemic treatment / Diabetes Care 40(Suppl 1):S64~74
Canadian Diabetes Association Clinical Practice Guidelines Expert Committee / 2013 / Pharmacologic management of type 2 diabetes / Can J Diabetes 37(Suppl 1):S61~68
Cimmaruta D / 2016 / Efficacy and safety of insulin-GLP-1 receptor agonists combination in type 2 diabetes mellitus: a systematic review / Expert Opin Drug Saf 15(sup2):77~83
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Cardiovascular Effects of Glucagon-Like Peptide-1 Receptor Agonists
Endocrinology and Metabolism
2016 .01
-
Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
Annals of Pediatirc Endocrinology & Metabolism
2017 .01
-
Peptidyl and Non-Peptidyl Oral Glucagon-Like Peptide-1 Receptor Agonists
Endocrinology and Metabolism
2021 .01
-
The Efficacy of Treatment Intensification by Quadruple Oral Therapy Compared to GLP-1RA Therapy in Poorly Controlled Type 2 Diabetes Mellitus Patients: A Real-world Data Study
Diabetes and Metabolism Journal
2023 .01
-
The Role of Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Understanding How Data Can Inform Clinical Practice in Korea
Diabetes and Metabolism Journal
2015 .01
-
Cardiovascular Outcome Trials of Incretin Therapy (Dipeptidyl Peptidase-4 Inhibitors/Glucagon-Like Peptide-1 Receptor Agonist)
지질·동맥경화학회지
2018 .01
-
Insulin/GLP-1 Treatment for Patients with DM
Journal of mucopolysaccharidosis and rare disease
2016 .01
-
GLP-1 Based Combination Therapy for Obesity and Diabetes
Journal of Obesity & Metabolic Syndrome
2017 .01
-
글루카곤양펩티드-1의 췌장 외 효과
대한내과학회지
2015 .01
-
Real-World Treatment Patterns according to Clinical Practice Guidelines in Patients with Type 2 Diabetes Mellitus and Established Cardiovascular Disease in Korea: Multicenter, Retrospective, Observational Study
Diabetes and Metabolism Journal
2024 .03
-
The Role of Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors in Reducing Cardiovascular Events in Patients with Type 2 Diabetes
Endocrinology and Metabolism
2019 .01
-
GLP regulation for medical device
한국실험동물학회 학술발표대회 논문집
2017 .08
-
A Review of the Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors on Lean Body Mass in Humans
Endocrinology and Metabolism
2019 .01
-
Effect of Glucagon-like Peptide-1 on the Differentiation of Adipose-derived Stem Cells into Osteoblasts and Adipocytes
대한폐경학회지
2015 .01
-
Application of GLP in biological testing for medical devices
한국실험동물학회 학술발표대회 논문집
2019 .07
-
Enhancing Patient Outcomes: Prioritizing SGLT2is and GLP-1RAs in Diabetes with CVD
Diabetes and Metabolism Journal
2024 .03
-
Glucagon-Like Peptide-1 Based Therapies: A New Horizon in Obesity Management
Endocrinology and Metabolism
2024 .04
-
The Road towards Triple Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Glucagon Receptor - An Update
Endocrinology and Metabolism
2024 .02
-
Clinical Efficacy of Sodium-Glucose Cotransporter 2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes Mellitus: Real-World Study
Diabetes and Metabolism Journal
2022 .07
-
Introduction to the non-clinical trials regulation for medical devices
한국실험동물학회 학술발표대회 논문집
2017 .08
이 논문의 저자 정보
최근 본 자료
댓글(0)
0